Eppendorf

Articles

This application note describes production of a recombinant protein using a workflow for culturing and harvesting bacteria and purifying proteins. The Eppendorf Centrifuge CR22N or CR30NX is used in combination with the Innova S44i Shaker for a high yield of functional recombinant protein.

Production of Recombinant Human Phosphoserine Phosphatase Using the Innova® S44i Shaker and the Centrifuge Harvesting Bundle 4 x 1.5 L

This white paper introduces a method for reducing harvesting time of yeast, bacteria, or cell cultures by up to 32% using the Eppendorf Centrifuge CR22N or CR30NX with unique triangular 1.5 L bottles.  

Unique 4 x 1.5 L Capacity Rotor for High-Speed Centrifuges CR22N and CR30NX

Did you know that running costs for a CO2 incubator easily exceed its purchase price over time? Learn how the CellXpert can help you to save money for your lab.

Saving Costs in Cell Culture

Contamination is associated with experimental repeats and project delays. In this White Paper we discuss the best strategies to prevent contamination in cell culture.


How to Remove Contamination in Cell Culture



Since the approval of the first biopharmaceutical in 1982, recombinant biopharmaceuticals have progressively become an important sector of the general pharmaceutical industry. Antibody products have played a key role in the recombinant sector and have evolved to be the largest percentage of marketed biopharmaceuticals, yielding the largest proportion of sales and constitute the vast majority of the developing pipeline. Reviewing how technologies have facilitated the growth of antibody products, a parallel view of technology implementation and antibody product growth will describe how antibodies developed so quickly into the dominant product group today and how new technologies may further influence these biopharmaceuticals.

With a focus on antibody products, this webinar provides insights into the current antibody product market and pipeline and the technologies responsible for facilitating the extensive growth of these products.

Understand the role of antibody products in the global pharmaceutical market

Learn how antibody types, expression systems and targets have evolved

Discover the past, current, and future technology drivers contributing to the phenomenal growth of antibody products


Senior Consultant and Managing Director
bioTRAK®

As a Senior Consultant and the Managing Director of bioTRAK® database Services within the BioProcess Technology Group of BDO, Dawn M. Ecker specializes in the forecasting of the supply and demand of biopharmaceutical products, providing clients with the industry’s premier biopharmaceutical market related analyses. The bioTRAK® data and market related analyses provided by Ms. Ecker have supported the biopharmaceutical industry enabling organizational acquisitions, manufacturing facility expansions, and general industry investments by providing unbiased data-driven analyses to the industry’s leading contract manufacturers, suppliers, product developers and investment firms around the world.

Webcasts

Wednesday October 27th, 2021 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Antibody products have evolved to be the cornerstone of the biopharmaceutical market and are a driving force in the pharmaceutical landscape. A variety of tools and technologies have contributed to the success and unrivaled growth of antibody products, learn how current and novel technologies may impact antibody product growth in the coming decades. 